Biothrax Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The biothrax market size has grown strongly in recent years. It will grow from $0.93 million in 2025 to $1.01 million in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to bioterrorism threat awareness, government-funded vaccine programs, military immunization requirements, historical anthrax exposure incidents, reliance on centralized vaccination campaigns.

The biothrax market size is expected to see strong growth in the next few years. It will grow to $1.4 million in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increased homeland security investments, rising global biodefense collaborations, expansion of emergency preparedness policies, growth in animal anthrax prevention programs, modernization of vaccine storage infrastructure. Major trends in the forecast period include rising focus on biodefense preparedness, expansion of government stockpiling programs, increased use of pre-exposure prophylaxis vaccination, growing emphasis on emergency response readiness, strengthening of national immunization security programs.

The increasing consumption of meat is expected to drive the growth of the BioThrax market going forward. Meat consumption is influenced by factors such as rapid urbanization, rising income levels, changing dietary habits, and cultural preferences that emphasize meat as a major source of protein and nutrition. BioThrax is used to vaccinate livestock against anthrax, a disease that can be transmitted through contaminated meat, thereby helping ensure meat safety and protecting public health from zoonotic disease outbreaks. For instance, in June 2023, according to the Food and Agriculture Organization of the United Nations, global meat production increased to 363.9 million metric tons in 2023. Thus, the rising consumption of meat is contributing to the growth of the BioThrax market.

The growing prevalence of anthrax is also expected to propel the growth of the BioThrax market going forward. Anthrax prevalence is largely driven by the persistence of Bacillus anthracis spores in soil, which can infect animals and humans through contact or ingestion. BioThrax is a vaccine that helps prevent anthrax by stimulating the immune system to produce antibodies against Bacillus anthracis, thereby reducing the risk of infection. For instance, in December 2023, according to the World Health Organization, Zambia reported 684 suspected human anthrax cases as of November 2023, including four deaths, corresponding to a case fatality ratio of 0.6%. Thus, the increasing prevalence of anthrax is driving the growth of the BioThrax market.

Major companies operating in the BioThrax market are concentrating on strategic investments to strengthen production capacity, expand their geographic reach, and develop advanced anthrax vaccines. Strategic funding supports clinical trials and helps meet regulatory requirements, enabling companies to secure approvals across multiple countries. This, in turn, improves the availability of vaccines in underserved regions. For instance, in January 2024, Emergent BioSolutions, a US-based biotechnology company, received a major contract valued at up to $235.8 million from the U.S. Department of Defense (DoD) to supply BioThrax (Anthrax Vaccine Adsorbed) for military use. This contract highlights the continued demand for effective anthrax vaccines within the U.S. military and demonstrates Emergent’s long-standing partnership with government agencies in delivering biodefense solutions.

Major companies operating in the biothrax market are Emergent Bio-Solutions.

North America was the largest region in the biothrax market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biothrax market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biothrax market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the biothrax market by increasing costs associated with imported vaccine ingredients, sterile vials, and cold-chain logistics equipment. These impacts have affected government procurement budgets, particularly in regions that rely on cross-border sourcing for biodefense vaccines. Hospital and vaccination center segments in regions such as asia-pacific and middle east are more sensitive to tariff-driven cost fluctuations. At the same time, tariffs have encouraged domestic vaccine manufacturing, strengthened national stockpiling capabilities, and improved long-term biodefense supply security.

The biothrax market research report is one of a series of new reports that provides biothrax market statistics, including biothrax industry global market size, regional shares, competitors with a biothrax market share, detailed biothrax market segments, market trends and opportunities, and any further data you may need to thrive in the biothrax industry. This biothrax market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biothrax is a vaccine developed to protect against anthrax, a serious and potentially life-threatening disease caused by the bacterium Bacillus anthracis. The vaccine functions by stimulating the immune system to generate antibodies against anthrax toxins, which can be fatal if exposure occurs, particularly in bioterrorism-related situations.

The main types in the Biothrax market include live vaccines and cell-free protective antigen vaccines. Live vaccines are produced from weakened, or attenuated, organisms that do not cause disease but effectively trigger a strong immune response. The clinical indications include pre-exposure prophylaxis and post-exposure prophylaxis. The vaccine is used for both human and animal applications, and the end users include hospitals, clinics, vaccination centers, and other healthcare facilities.

The biothrax market consists of sales of single-dose vials and multi-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.